Mori A型颅内椎基底动脉重度狭窄病人支架与药物治疗近期疗效比较  

The comparison between stenting and aggressive medical therapy for severe symptomatic intracranial Mori A type vertebrobasilar artery stenosis

作　　者：白雪[1] 高晓梅[1] 张亚丽[1] 刘丽[1] 安翼[1] 张晶晶[1] 

机构地区：[1]赤峰市医院神经内科,内蒙古赤峰024000

出　　处：《安徽医药》2017年第2期286-289,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：目的比较Mori A型颅内椎基底动脉重度狭窄血管内支架成形术与单纯药物治疗疗效上的差异。方法回顾性分析122例Mori A型颅内椎基底动脉重度狭窄病人的临床资料,按处理方法不同分为药物组和支架组,主要终点事件定义为缺血性卒中、短暂性脑缺血发作(TIA)或死亡。比较两组间围手术期及1年内主要终点事件及mRS评分的差异。结果两组30 d内主要终点事件发生率(5.8%vs 13.2%)差异无统计学意义(P=0.272)。1年随访期内支架组累积无终点事件发生率明显高于药物组(92.8%vs 74.2%,P<0.05),支架组改良RANKIN量表(mRS)评分≤2分病人比例明显高于药物组(92.8%vs75.5%,P<0.01)。结论对于Mori A型颅内椎基底动脉重度狭窄病人,支架置入治疗安全、有效,1年内预防再缺血效果优于单纯药物治疗。Objective To compare the curative effect between stenting and aggressive medical therapy for severe symptomatic intracra-nial Mori A type vertebrobasilar artery stenosis. Method A retrospective study was carried out by analyzing the medical records about 122 cases with severe symptomatic Mori A type intracranial vertebrobasilar artery stenosis. The patients were divided into drug treatment group and stenting group. The primary outcome was defined as stroke,transient ischemic attack （TIA） and death. The primary outcome and mRS scores were compared between the two groups. Results There was no difference of the rate of 30-day primary outcome（5. 8% vs 13.2%） between the two groups （P = 0.272） . The incidence of accumulative non-primary outcomes and proportion of mRs scores^ 2 in stenting group were higher than those in drug treatment group in the one year （respectively,92. S% vs 74. 2% ,P 〈0.05 ; 92. 8% 仍 75. 5%,P 〈0. 01）. Conclusion For the patients with severe symptomatic Mori A type intracranial vertebrobasilar artery stenosis, endovascular stenting was safe and effective, which was better than drug treatment in prevention of re-ischemia within one year.

关 键 词：颅内椎基底动脉狭窄 支架治疗 药物治疗 Mori A型 

分 类 号：R651.1[医药卫生—外科学]